CRISPR Therapeutics CRSP Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's other non-current liabilities?
- CRISPR Therapeutics (CRSP) reported other non-current liabilities of $5.95M in Q1 2026.
- How has CRISPR Therapeutics's other non-current liabilities changed year-over-year?
- CRISPR Therapeutics's other non-current liabilities increased by 79.2% year-over-year, from $3.32M to $5.95M.
- What is the long-term trend for CRISPR Therapeutics's other non-current liabilities?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's other non-current liabilities has grown at a -4.2% compound annual growth rate (CAGR), from $7.63M to $6.14M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.